GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » YoY EPS Growth

Aptevo Therapeutics (Aptevo Therapeutics) YoY EPS Growth : 68.08% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Aptevo Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 was 68.08%.

Aptevo Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-13.34.

Aptevo Therapeutics YoY EPS Growth Historical Data

The historical data trend for Aptevo Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics YoY EPS Growth Chart

Aptevo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.58 62.27 -16.06 125.86 -190.45

Aptevo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.20 125.16 -122.04 66.67 68.08

Aptevo Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Aptevo Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-62.48-69.08)/ | 69.08 |
=-190.45 %

Aptevo Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-13.341--41.8)/ | -41.8 |
=68.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptevo Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » YoY EPS Growth
Comparable Companies
PTIX SXTP GRI REVB ARTL ARDS PSTV ATXI FWBI ELOX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AP8N:Germany
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Website
https://www.aptevotherapeutics.com
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121